A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 1,246,475 shares of BMY stock, worth $64.5 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares
1,246,475
Previous 1,177,752 5.84%
Holding current value
$64.5 Million
Previous $63.9 Million 18.95%
% of portfolio
0.26%
Previous 0.12%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 30, 2024

BUY
$40.25 - $52.99 $2.77 Million - $3.64 Million
68,723 Added 5.84%
1,246,475 $51.8 Million
Q1 2024

May 01, 2024

BUY
$47.98 - $54.4 $36.6 Million - $41.5 Million
763,213 Added 184.11%
1,177,752 $63.9 Million
Q4 2023

Jan 24, 2024

SELL
$48.48 - $57.85 $2.35 Million - $2.81 Million
-48,525 Reduced 10.48%
414,539 $21.3 Million
Q3 2023

Oct 26, 2023

BUY
$57.89 - $64.73 $785,104 - $877,868
13,562 Added 3.02%
463,064 $26.9 Million
Q2 2023

Aug 10, 2023

SELL
$63.71 - $70.74 $7.55 Million - $8.39 Million
-118,575 Reduced 20.87%
449,502 $28.7 Million
Q1 2023

May 04, 2023

BUY
$65.71 - $74.53 $2.77 Million - $3.14 Million
42,095 Added 8.0%
568,077 $39.4 Million
Q4 2022

Feb 09, 2023

BUY
$68.48 - $81.09 $2.66 Million - $3.15 Million
38,827 Added 7.97%
525,982 $37.8 Million
Q3 2022

Nov 10, 2022

BUY
$0.13 - $76.84 $6,314 - $3.73 Million
48,572 Added 11.07%
487,155 $34.6 Million
Q2 2022

Jul 26, 2022

BUY
$72.62 - $79.98 $5.1 Million - $5.61 Million
70,167 Added 19.05%
438,583 $33.8 Million
Q1 2022

May 10, 2022

BUY
$61.48 - $73.72 $202,884 - $243,276
3,300 Added 0.9%
368,416 $26.9 Million
Q4 2021

Feb 08, 2022

BUY
$53.63 - $62.52 $3.59 Million - $4.18 Million
66,890 Added 22.43%
365,116 $22.8 Million
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $2.61 Million - $3.05 Million
44,067 Added 17.34%
298,226 $17.6 Million
Q2 2021

Aug 11, 2021

BUY
$61.91 - $67.42 $2.1 Million - $2.29 Million
33,972 Added 15.43%
254,159 $17 Million
Q1 2021

May 13, 2021

SELL
$59.34 - $66.74 $5.63 Million - $6.33 Million
-94,905 Reduced 30.12%
220,187 $13.9 Million
Q4 2020

Feb 10, 2021

BUY
$57.74 - $65.43 $2.08 Million - $2.36 Million
36,007 Added 12.9%
315,092 $19.5 Million
Q3 2020

Nov 12, 2020

BUY
$57.43 - $63.64 $861,450 - $954,600
15,000 Added 5.68%
279,085 $16.8 Million
Q2 2020

Aug 11, 2020

SELL
$54.82 - $64.09 $1.99 Million - $2.33 Million
-36,327 Reduced 12.09%
264,085 $15.5 Million
Q1 2020

May 12, 2020

BUY
$46.4 - $67.43 $2.23 Million - $3.24 Million
48,057 Added 19.04%
300,412 $16.7 Million
Q4 2019

Feb 12, 2020

BUY
$49.21 - $64.19 $1.11 Million - $1.45 Million
22,570 Added 9.82%
252,355 $16.2 Million
Q3 2019

Nov 12, 2019

BUY
$42.77 - $50.71 $1.07 Million - $1.27 Million
24,984 Added 12.2%
229,785 $11.7 Million
Q2 2019

Aug 13, 2019

BUY
$44.62 - $49.34 $808,023 - $893,498
18,109 Added 9.7%
204,801 $9.27 Million
Q1 2019

May 13, 2019

SELL
$45.12 - $53.8 $1.14 Million - $1.36 Million
-25,273 Reduced 11.92%
186,692 $8.92 Million
Q4 2018

Feb 11, 2019

SELL
$48.76 - $63.23 $1.26 Million - $1.63 Million
-25,779 Reduced 10.84%
211,965 $11 Million
Q3 2018

Nov 13, 2018

BUY
$55.19 - $62.25 $3.23 Million - $3.64 Million
58,445 Added 32.6%
237,744 $14.8 Million
Q2 2018

Aug 14, 2018

BUY
$50.53 - $62.98 $200,048 - $249,337
3,959 Added 2.26%
179,299 $9.92 Million
Q1 2018

May 10, 2018

BUY
$59.92 - $68.98 $1.08 Million - $1.24 Million
18,028 Added 11.46%
175,340 $11.1 Million
Q4 2017

Feb 12, 2018

BUY
$59.94 - $65.35 $491,088 - $535,412
8,193 Added 5.49%
157,312 $9.64 Million
Q3 2017

Nov 08, 2017

BUY
$55.23 - $63.74 $701,144 - $809,179
12,695 Added 9.31%
149,119 $9.48 Million
Q2 2017

Aug 14, 2017

BUY
N/A
136,424
136,424 $7.6 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $110B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Mirae Asset Global Investments Co., Ltd. Portfolio

Follow Mirae Asset Global Investments Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.